inhibitory glp 1 GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Frontiers | Clinical Use of

Table 1 ), demonstrating that the recombinant proteins of AsGGT1, AsGGT2, and AsGGT3 can convert -glutamyl- S -allyl-L-cysteine to S -allyl-L-cysteine

The term GLP-1s refers to medications that mimic or activate the hormone glucagonlike peptide1

These questions must now guide the next phase of research, moving beyond foundational discoveries toward translational application

Moreover, the treatment of neurodevelopmental disorders, as FXS, require the delivery of molecules to the brain, accounting for the crossing of the bloodbrain barrier (BBB), that could limit the access of peptides to the central nervous system (CNS)